This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, R N Articles by Pfaller, M A Search for Related Content PubMed PubMed Citation Articles by Jones, R N Articles by Pfaller, M A

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 April; 33(4): 562-565

Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Clinical Microbiology Institute, Tualatin, Oregon 97062.

ABSTRACT

A new carbapenem, SM-7338, was compared with imipenem, cefotaxime, and ceftazidime at five medical centers. Nearly 6,000 strains were tested by reference methods of the National Committee for Clinical Laboratory Standards, and SM-7338 inhibited the largest percentage of gram-negative bacilli. Its spectrum included all members of the family Enterobacteriaceae (99.7% were susceptible to less than or equal to 4 micrograms/ml), Pseudomonas spp. (but not Xanthomonas maltophilia), and Acinetobacter spp. The potency and spectrum of SM-7338 against the gram-positive organisms were less than those of imipenem and superior to those of ceftazidime. Only the enterococci and some oxacillin-resistant staphylococci were less susceptible to SM-7338 (MICs for 90% of isolates, greater than or equal to 8 micrograms/ml). Organisms resistant to ceftazidime were generally susceptible to SM-7338 and imipenem (76%). However, for one-third of the imipenem-resistant gram-negative bacilli (MICs, greater than 8 micrograms/ml), SM-7338 MICs were less than or equal to 4 micrograms/ml. Some endemic differences in patterns of SM-7338 activity against selected gram-negative species were found among some medical centers.

This article has been cited by other articles:

• Park, S. W., We, J. S., Kim, G. W., Choi, S. H., Park, H. S. (2002). Stability of New Carbapenem DA-1131 to Renal Dipeptidase (Dehydropeptidase I). Antimicrob. Agents Chemother. 46: 575-577 [Abstract] [Full Text]  
• Hsueh, P.-R., Teng, L.-J., Pan, H.-J., Chen, Y.-C., Sun, C.-C., Ho, S.-W., Luh, K.-T. (1998). Outbreak of Pseudomonas fluorescens Bacteremia among Oncology Patients. J. Clin. Microbiol. 36: 2914-2917 [Abstract] [Full Text]